Sands Capital Ventures’s Acumen Pharmaceuticals ABOS Stock Holding History

Sands Capital Ventures’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.26M	Hold	3,720,105	–	–	1.19%	16
2026 Q2	$9.9M	Hold	3,720,105	–	–	1.62%	15
2026 Q1	$8.78M	Buy	3,720,105 +303,030	+9%	+$773K	2.08%	12
2025 Q4	$7.21M	Hold	3,417,075	–	–	1.39%	14
2025 Q3	$5.84M	Hold	3,417,075	–	–	1.28%	13
2025 Q2	$3.96M	Hold	3,417,075	–	–	0.78%	15
2025 Q1	$3.76M	Hold	3,417,075	–	–	0.92%	17
2024 Q4	$5.88M	Hold	3,417,075	–	–	1.28%	15
2024 Q3	$8.47M	Hold	3,417,075	–	–	2.38%	9
2024 Q2	$8.27M	Hold	3,417,075	–	–	2.77%	8
2024 Q1	$13.8M	Hold	3,417,075	–	–	3.34%	7
2023 Q4	$13.1M	Hold	3,417,075	–	–	3.65%	7
2023 Q3	$14.2M	Hold	3,417,075	–	–	4.2%	10
2023 Q2	$16.4M	Hold	3,417,075	–	–	4.86%	8
2023 Q1	$13.9M	Hold	3,417,075	–	–	3.43%	10
2022 Q4	$18.5M	Hold	3,417,075	–	–	5.05%	8
2022 Q3	$34.3M	Hold	3,417,075	–	–	9.96%	5
2022 Q2	$16.1M	Hold	3,417,075	–	–	4.41%	10
2022 Q1	$13.4M	Hold	3,417,075	–	–	2.79%	9
2021 Q4	$23.1M	Hold	3,417,075	–	–	3.42%	8
2021 Q3	$50.8M	Buy	+3,417,075	New	+$56.9M	7.66%	5

Other funds holding ABOS

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Knollwood Investment Advisory Hunt Valley, Maryland $1.18B AUM 37.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $33B AUM 30.04% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $36.2B AUM 20.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Sands Capital Ventures's ABOS Position: Q3 2026 in Review

Sands Capital Ventures held its Acumen Pharmaceuticals (ABOS) position steady in Q3 2026 at 3,720,105 shares worth $8.26M. The position accounts for 1.19% of the portfolio, ranked #16.

Sands Capital Ventures first reported a position in ABOS in Q3 2021 and has held it in 21 quarters since. The position peaked at $50.8M in Q3 2021. 67 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

Sands Capital Ventures held 3,720,105 shares of Acumen Pharmaceuticals worth $8.26M as of Q3 2026.
Sands Capital Ventures left its Acumen Pharmaceuticals share count unchanged in Q3 2026.
Acumen Pharmaceuticals made up 1.19% of Sands Capital Ventures's portfolio in Q3 2026, its #16 holding.
Sands Capital Ventures first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 21 quarters since.
Sands Capital Ventures's Acumen Pharmaceuticals position peaked at $50.8M in Q3 2021.
67 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on Sands Capital Ventures's 13F filing for Q3 2026, filed 13 Nov 2026.